Object: The novel severe acute respiratory syndrome MESHD (SARS)-CoV-2 outbreak has been declared a pandemic in March, 2020. An increasing body of evidence suggests that patients with the coronavirus disease MESHD (COVID-19) might have a heterogeneous spectrum of neurological symptomsMethods. A systematic search of two databases was performed for studies published up to April 17th, 2020. PRISMA guidelines were followed.Results: We included 13 studies evaluating 2499 patients with laboratory-confirmed COVID-19 infections MESHD. The median age TRANS of patients was 50.3 (IQR 9.6), and the rate of male TRANS patients was 50% (95% CI 47.9-52%). The most common reported comorbidities were hypertension MESHD hypertension HP and diabetes (18.7%, 95% CI 16.9-20.7% and 9%, 95% CI 7.4-11.3%, respectively). Headache MESHD Headache HP was reported in 17.9% of patients (95% CI 16.1-19.8%), and dizziness MESHD in 13.9% (95% CI 10.7-18%). Fatigue MESHD Fatigue HP or myalgia MESHD myalgia HP, hypo/ anosmia HP, and gustatory dysfunction were reported in 24%, 55.2%, and 55.4%, of patients, respectively.Conclusions: These data support accumulating evidence that a significant proportion of patients with COVID-19 infection MESHD develop neurological manifestations, especially olfactory and gustatory dysfunction. The pathophysiology of this association is under investigation and warrants additional studies, Physicians should be aware of this possible association because during the epidemic period of COVID-19, early recognition of neurologic manifestations MESHD otherwise not explained would raise the suspect of acute respiratory syndrome MESHD coronavirus 2 infection MESHD.